Asciminib with or without dasatinib for second-line chronic myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug combination for people with chronic myeloid leukemia (CML) that has not responded well enough to their first treatment. The goal is to see if adding or combining these drugs can better control the leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have chronic-phase CML with a specific genetic change (BCR::ABL1) and your first TKI treatment is not working well enough or you cannot tolerate it.
- You have not had a stem cell or bone marrow transplant.
- You have not taken asciminib before.
- Your heart, liver, and kidney function must be within the required limits.
- You must not have other active cancers or certain heart, bleeding, or pancreas conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill, asciminib, as the first treatment for people newly diagnosed with chronic myeloid leukemia (CML) in its early phase. The goal is to see if it can control the disease with fewer side effects than standard treatments.
This study tests a pill called asciminib for people with chronic phase CML whose first targeted therapy didn't work or caused side effects. The goal is to see if asciminib can better control the disease with fewer problems.
This study tests whether the drug asciminib is safe and works well for people with chronic myeloid leukemia, compared to standard TKIs. You may join if you're newly diagnosed or have tried only one previous TKI treatment.
This trial tests the drug asciminib for people newly diagnosed with chronic myeloid leukemia (CML) who have been on treatment for less than a month. It aims to see if early treatment with asciminib is safe and effective.
This trial tests a combination of two drugs, dasatinib and ropeginterferon, for people newly diagnosed with chronic myeloid leukemia (CML) in its early chronic phase. The goal is to see if the combination works safely and helps control the disease.
This study tests a targeted pill called asciminib for people newly diagnosed with chronic-phase CML. It aims to see if this drug is safe and effective as an early treatment option.
Hear when a new Chronic Myeloid Leukemia (CML) in trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.